DSGN on Nasdaq

Design Therapeutics, Inc.

American pharmaceutical preparations company, incorporated in Delaware. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Regen BioPharma Inc, Geron Corporation or Anixa Biosciences Inc, or pick any stock.

TickerDSGN on Nasdaq¹
IndustryPharmaceutical Preparations¹
HeadquartersCarlsbad, California¹
Incorporated inDE²
Business address6005 Hidden Valley Road, Suite 110, Carlsbad, Ca 92011²
Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-32.8%Return on equity³

-$54.6MFree cash flow³

Financial statements

Revenue⁴⁵³$0 in 2025

Operating income⁴⁶⁷⁵³-$79.5M in 2025+854% since 2020

Net income⁴⁶⁷⁵³-$69.8M in 2025+743% since 2020

Every line of the income statement as filed: the last 2 fiscal years, latest first.³

Period ending	2025-12-31	2024-12-31
Research and development (including related party amounts of $915 and $891, respectively)	$59.1M	$44.4M
General and administrative (including related party amounts of $528 and $537, respectively)	$20.3M	$18.0M
Total operating expenses	$79.5M	$62.4M
Loss from operations	-$79.5M	-$62.4M
Interest income	$9.7M	$12.8M
Net loss	-$69.8M	-$49.6M
Net loss per share, basic	-$1.22	-$0.88
Net loss per share, diluted	-$1.22	-$0.88
Weighted-average shares of common stock outstanding, basic	57.3M shares	56.6M shares
Weighted-average shares of common stock outstanding, diluted	57.3M shares	56.6M shares

Total assets⁴⁶⁷⁵³$226.2M in 2025+519% since 2020

Total liabilities⁴⁶⁷⁵³$13.7M in 2025+454% since 2020

Shareholders’ equity⁴⁶⁷⁵³$212.5M in 2025

Cash⁴⁶⁷⁵³$16.9M in 2025+21791% since 2019

Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.³

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$16.9M	$22.6M
Investment securities	$203.0M	$222.9M
Prepaid expenses and other current assets	$3.9M	$2.6M
Total current assets	$223.8M	$248.0M
Property and equipment, net	$981.0K	$1.4M
Right-of-use asset, related party	$1.4M	$2.2M
Other assets	$0	$427.0K
Total assets	$226.2M	$252.1M
Accounts payable	$2.3M	$2.2M
Accrued expenses and other current liabilities (including related party amounts of $890 and $800, respectively)	$10.7M	$6.3M
Total current liabilities	$13.1M	$8.5M
Operating lease liability, net, related party	$645.0K	$1.5M
Total liabilities	$13.7M	$10.0M
Common stock: $0.0001 par value; 200,000,000 shares authorized, 60,398,051 and 56,754,341 shares issued and outstanding at December 31, 2025 and 2024, respectively	$6.0K	$6.0K
Additional paid-in capital	$509.1M	$468.8M
Accumulated deficit	-$297.0M	-$227.2M
Accumulated other comprehensive income	$403.0K	$475.0K
Total stockholders' equity	$212.5M	$242.1M	$277.7M
Total liabilities and stockholders' equity	$226.2M	$252.1M
Accrued expenses and other current liabilities, related party amounts	$890.0K	$800.0K
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	200.0M shares	200.0M shares
Common stock, shares issued	60.4M shares	56.8M shares
Common stock, shares outstanding	60.4M shares	56.8M shares

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$16.9M	$22.6M
Investment securities	$203.0M	$222.9M
Prepaid expenses and other current assets	$3.9M	$2.6M
Total current assets	$223.8M	$248.0M
Property and equipment, net	$981.0K	$1.4M
Right-of-use asset, related party	$1.4M	$2.2M
Other assets	$0	$427.0K
Total assets	$226.2M	$252.1M
Accounts payable	$2.3M	$2.2M
Accrued expenses and other current liabilities (including related party amounts of $890 and $800, respectively)	$10.7M	$6.3M
Total current liabilities	$13.1M	$8.5M
Operating lease liability, net, related party	$645.0K	$1.5M
Total liabilities	$13.7M	$10.0M
Common stock: $0.0001 par value; 200,000,000 shares authorized, 60,398,051 and 56,754,341 shares issued and outstanding at December 31, 2025 and 2024, respectively	$6.0K	$6.0K
Additional paid-in capital	$509.1M	$468.8M
Accumulated deficit	-$297.0M	-$227.2M
Accumulated other comprehensive income	$403.0K	$475.0K
Total stockholders' equity	$212.5M	$242.1M	$277.7M
Total liabilities and stockholders' equity	$226.2M	$252.1M
Accrued expenses and other current liabilities, related party amounts	$890.0K	$800.0K
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	200.0M shares	200.0M shares
Common stock, shares issued	60.4M shares	56.8M shares
Common stock, shares outstanding	60.4M shares	56.8M shares

Cash from operations⁴⁶⁷⁵³-$54.4M in 2025+527% since 2020

Capital spending⁴⁶⁷⁵³$193.0K in 2025+154% since 2020

Free cash flow⁴⁶⁷⁵³-$54.6M in 2025+524% since 2020

Every line of the cash flow as filed: the last 2 fiscal years, latest first.³

Period ending	2025-12-31	2024-12-31
Net loss	-$69.8M	-$49.6M
Depreciation	$622.0K	$596.0K
Stock-based compensation	$14.5M	$13.1M
Amortization of premiums on investment securities, net	-$3.3M	-$6.2M
Non-cash lease expense	-$21.0K	$6.0K
Deferred financing costs	$427.0K	$0
Prepaid expense and other assets	-$1.4M	$226.0K
Accounts payable and other liabilities	$4.5M	-$1.2M
Net cash used in operating activities	-$54.4M	-$43.1M
Purchases of investment securities	-$291.8M	-$230.2M
Proceeds from maturities of investment securities	$314.9M	$274.5M
Purchases of property and equipment	-$193.0K	-$340.0K
Net cash provided by investing activities	$22.9M	$44.0M
Proceeds from the issuance of common stock in at-the-market offering, net of issuance costs	$24.8M	$0
Proceeds from the exercise of stock options	$242.0K	$36.0K
Issuance of common stock through employee stock purchase plan	$649.0K	$477.0K
Net cash provided by financing activities	$25.7M	$513.0K
Net decrease in cash and cash equivalents	-$5.7M	$1.4M
Issuance costs included in accrued expenses	$17.0K	$0

Compare Design Therapeutics, Inc. with another company

Leadership

Who has led Design Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

Chair

Pratik Shah2021–now

President

Chief operating officer

Sean Jeffries2021–now

2025

Chief executive officerPratik Shah Sep 5, 2023 to now¹⁰
Chief executive officerJoao Siffert Md. Mar 25, 2021 to Feb 3, 2023¹¹
ChairPratik Shah Mar 25, 2021 to now¹²
PresidentPratik Shah Sep 5, 2023 to now¹⁰
PresidentJoao Siffert Md. Mar 25, 2021 to Feb 3, 2023¹¹
Chief operating officerSean Jeffries Mar 25, 2021 to now¹³

Board members and other officers (14)

Chief Medical OfficerChris Storgard May 23, 2025 to now¹⁴
Vice President, FinanceJustin Thacker Mar 25, 2021 to Apr 1, 2021¹⁵
Principal Accounting OfficerDawn Giangiulio Aug 17, 2021 to Aug 17, 2021¹⁶
Chief Accounting OfficerJulie Burgess Sep 20, 2021 to now¹⁷
Board memberJustin D. Gover Sep 10, 2025 to now¹⁸
Board memberArsani William Mar 25, 2021 to now¹⁹
Board memberBihua Chen Mar 25, 2021 to Mar 25, 2021²⁰
Board memberJoao Siffert Md. Mar 25, 2021 to Feb 3, 2023¹¹
Board memberJohn P. Schmid Mar 25, 2021 to now²¹
Board memberRodney W. Lappe Mar 25, 2021 to now²²
Board memberSimeon George Mar 25, 2021 to now²³
Board memberStella Xu Mar 25, 2021 to Jun 2, 2023²⁴
Board memberDeepa Prasad Jun 16, 2021 to now²⁵
Board memberHeather Behanna Jun 16, 2021 to now²⁶

Timeline

Sep 5, 2023New chief executive Pratik Shah becomes CEO¹⁰
Mar 25, 2021New chief executive Joao Siffert Md. becomes CEO¹¹

Filings

197 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 32 major events, 80 insider forms, 30 large holders, 35 other. The latest 20:

Aug 14, 2026SCHEDULE 13G/A EDGAR
Aug 14, 2026SCHEDULE 13G EDGAR
Aug 3, 202610-Q EDGAR
Aug 3, 20268-K EDGAR
Jun 11, 20264 EDGAR
Jun 11, 20264 EDGAR
Jun 11, 20264 EDGAR
Jun 11, 20264 EDGAR
Jun 11, 20264 EDGAR
Jun 11, 20264 EDGAR
Jun 11, 20268-K EDGAR
Jun 9, 2026SCHEDULE 13G EDGAR
May 18, 20268-K EDGAR
May 15, 2026SCHEDULE 13G/A EDGAR
Apr 28, 202610-Q EDGAR
Apr 28, 20268-K EDGAR
Apr 23, 2026DEFA14A EDGAR
Apr 23, 2026DEF 14A EDGAR
Apr 23, 2026ARS EDGAR
Apr 1, 20264 EDGAR

The 197 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

23 open-market trades by officers, directors and large owners since October 2021: 17 buys and 6 sales. Grants, option exercises and gifts are left out.

Date	Who	Trade	Shares	Price	Value	Filing
Aug 13, 2025	William ArsaniDirector	Sale	562,627	$5.25	$3.0M	Form 4
Dec 18, 2024	Prasad DeepaDirector	Sale	3,806	$6.27	$23.9K	Form 4
Aug 9, 2024	William ArsaniDirector	Sale	814,874	$4.25	$3.5M	Form 4
Mar 25, 2024	Schmid John P.Director	Buy	17,809	$3.74	$66.6K	Form 4
Mar 25, 2024	Berger Heather A.Director	Buy	1,300	$3.74	$4.9K	Form 4
Mar 22, 2024	Schmid John P.Director	Buy	9,156	$3.62	$33.1K	Form 4
Sep 29, 2023	LAPPE RODNEY WDirector	Buy	21,000	$2.35	$49.4K	Form 4
Aug 29, 2023	Prasad DeepaDirector	Buy	12,000	$2.31	$27.7K	Form 4
Aug 29, 2023	William ArsaniDirector	Buy	1,960,000	$2.44	$4.8M	Form 4
Aug 28, 2023	William ArsaniDirector	Buy	275,000	$2.15	$591.2K	Form 4
Dec 20, 2022	Siffert Joao MDPresident and CEO	Buy	6,300	$8.38	$52.8K	Form 4
Dec 20, 2022	George SimeonDirector	Buy	40,000	$8.14	$325.6K	Form 4
Dec 20, 2022	SR ONE CAPITAL PARTNERS I, LP10% owner	Buy	40,000	$8.14	$325.6K	Form 4
Dec 19, 2022	Siffert Joao MDPresident and CEO	Buy	1,150	$8.47	$9.7K	Form 4
Dec 19, 2022	George SimeonDirector	Buy	360,000	$8.63	$3.1M	Form 4
Dec 19, 2022	SR ONE CAPITAL PARTNERS I, LP10% owner	Buy	360,000	$8.63	$3.1M	Form 4
Dec 16, 2022	George SimeonDirector	Buy	500,000	$8.28	$4.1M	Form 4
Dec 16, 2022	SR ONE CAPITAL PARTNERS I, LP10% owner	Buy	500,000	$8.28	$4.1M	Form 4
Dec 9, 2022	LAPPE RODNEY WDirector	Buy	15,000	$7.96	$119.4K	Form 4
Mar 22, 2022	Xu StellaDirector	Sale	1,455	$18.63	$27.1K	Form 4

All 23 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Point72 Asset Management, L.P.SCHEDULE 13G/A, 5 filings Aug 28, 2025 to Aug 14, 2026²⁷
Sirenia Capital Management LPSCHEDULE 13G, 1 filing Aug 14, 2026²⁸
SR One Capital Fund I Aggregator LPSCHEDULE 13D/A, 2 filings Dec 22, 2022 to Mar 11, 2026²⁹
Logos Global Management LPSCHEDULE 13D/A, 4 filings Mar 31, 2022 to Nov 18, 2025³⁰
Light Irrevocable Trust #1 dated April 22, 2019SCHEDULE 13G/A, 2 filings Feb 9, 2022 to Feb 7, 2025³¹
Star Irrevocable Trust #1 dated April 22, 2019SCHEDULE 13G/A, 2 filings Feb 9, 2022 to Feb 7, 2025³²
CITADEL ADVISORS LLCSC 13G/A, 4 filings Dec 22, 2022 to Feb 14, 2024³³
Cormorant Asset Management, LPSC 13G/A, 3 filings Feb 14, 2022 to Feb 14, 2024³⁴
State Street CorporationSC 13G/A, 2 filings Feb 8, 2023 to Jan 23, 2024³⁵
RA CAPITAL MANAGEMENT, L.P.SC 13G/A, 2 filings Oct 13, 2022 to Nov 14, 2023³⁶
Aseem Z. AnsariSC 13G, 1 filing Feb 9, 2022³⁷

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
SR One Capital Management, LP	6,526,476	$94.4M	9.1%	No change
Logos Global Management LP	3,000,000	$43.4M	1.9%	+1,050,000
Baker Bros. Advisors LP	2,678,430	$38.8M	0.2%	+92,452
Driehaus Capital Management LLC	2,661,115	$38.5M	0.2%	+916,128
BlackRock, Inc.	2,660,024	$38.5M	0.0%	+526,260
Point72 Asset Management, L.P.	2,366,453	$34.2M	0.1%	−356,301
Trails Edge Capital Partners, LP	2,001,282	$29.0M	4.6%	+1,149,269
Frazier Life Sciences Management, L.P.	1,809,854	$26.2M	0.6%	New
Vivo Capital, LLC	1,612,903	$23.3M	2.1%	No change
Vanguard Capital Management LLC	1,571,022	$22.7M	0.0%	+221,172
Caption Management, LLC	1,118,098	$16.2M	0.6%	+1,031,390
Almitas Capital LLC	1,026,893	$14.9M	3.6%	−503,442
Geode Capital Management, LLC	958,417	$13.9M	0.0%	+265,899
Sofinnova Investments, Inc.	865,135	$12.5M	0.7%	New
Fmr LLC	776,462	$11.2M	0.0%	−21,949
Morgan Stanley	765,425	$11.1M	0.0%	+108,860
State Street Corp	736,221	$10.7M	0.0%	+76,646
Woodline Partners LP	700,354	$10.1M	0.0%	−261,147
Dimensional Fund Advisors LP	694,743	$10.1M	0.0%	+262,903
Goldman Sachs Group Inc	656,584	$9.5M	0.0%	+151,866
Jacobs Levy Equity Management, Inc	565,597	$8.2M	0.0%	+276,212
Siren, L.L.C.	523,212	$7.6M	0.2%	New
Qube Research & Technologies Ltd	437,079	$6.3M	0.0%	+402,896
Renaissance Technologies LLC	387,913	$5.6M	0.0%	−20,287
Kennedy Capital Management LLC	384,036	$5.6M	0.1%	+112,482

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARDesign Therapeutics, Inc. filings on SEC EDGAR
2
SEC EDGARDesign Therapeutics, Inc. filings on SEC EDGAR
3
SEC EDGARDesign Therapeutics, Inc. 10-K for fiscal 2025
4
SEC EDGARDesign Therapeutics, Inc. 10-K for fiscal 2020
5
SEC EDGARDesign Therapeutics, Inc. 10-K for fiscal 2024
6
SEC EDGARDesign Therapeutics, Inc. 10-K for fiscal 2021
7
SEC EDGARDesign Therapeutics, Inc. 10-K for fiscal 2022
8
SEC EDGARDesign Therapeutics, Inc. 10-Q for fiscal 2026
9
SEC EDGARDesign Therapeutics, Inc. 10-Q for fiscal 2026
10
SEC EDGARPratik Shah, Chief executive officer
11
SEC EDGARJoao Siffert Md., Chief executive officer
12
SEC EDGARPratik Shah, Chair
13
SEC EDGARSean Jeffries, Chief operating officer
14
SEC EDGARChris Storgard, Chief Medical Officer
15
SEC EDGARJustin Thacker, Vice President, Finance
16
SEC EDGARDawn Giangiulio, Principal Accounting Officer
17
SEC EDGARJulie Burgess, Chief Accounting Officer
18
SEC EDGARJustin D. Gover, Board member
19
SEC EDGARArsani William, Board member
20
SEC EDGARBihua Chen, Board member
21
SEC EDGARJohn P. Schmid, Board member
22
SEC EDGARRodney W. Lappe, Board member
23
SEC EDGARSimeon George, Board member
24
SEC EDGARStella Xu, Board member
25
SEC EDGARDeepa Prasad, Board member
26
SEC EDGARHeather Behanna, Board member
27
SEC EDGARPoint72 Asset Management, L.P. SCHEDULE 13G/A on Design Therapeutics, Inc.
28
SEC EDGARSirenia Capital Management LP SCHEDULE 13G on Design Therapeutics, Inc.
29
SEC EDGARSR One Capital Fund I Aggregator LP SCHEDULE 13D/A on Design Therapeutics, Inc.
30
SEC EDGARLogos Global Management LP SCHEDULE 13D/A on Design Therapeutics, Inc.
31
SEC EDGARLight Irrevocable Trust #1 dated April 22, 2019 SCHEDULE 13G/A on Design Therapeutics, Inc.
32
SEC EDGARStar Irrevocable Trust #1 dated April 22, 2019 SCHEDULE 13G/A on Design Therapeutics, Inc.
33
SEC EDGARCITADEL ADVISORS LLC SC 13G/A on Design Therapeutics, Inc.
34
SEC EDGARCormorant Asset Management, LP SC 13G/A on Design Therapeutics, Inc.
35
SEC EDGARState Street Corporation SC 13G/A on Design Therapeutics, Inc.
36
SEC EDGARRA CAPITAL MANAGEMENT, L.P. SC 13G/A on Design Therapeutics, Inc.
37
SEC EDGARAseem Z. Ansari SC 13G on Design Therapeutics, Inc.